nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—AGTR1—endothelium—acquired immunodeficiency syndrome	0.0297	0.246	CbGeAlD
Azilsartan medoxomil—AGTR1—blood plasma—acquired immunodeficiency syndrome	0.0264	0.219	CbGeAlD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Amprenavir—acquired immunodeficiency syndrome	0.021	0.0292	CcSEcCtD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Nelfinavir—acquired immunodeficiency syndrome	0.0167	0.0232	CcSEcCtD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Abacavir—acquired immunodeficiency syndrome	0.0164	0.0228	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Didanosine—acquired immunodeficiency syndrome	0.0142	0.0198	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Didanosine—acquired immunodeficiency syndrome	0.0134	0.0187	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Nelfinavir—acquired immunodeficiency syndrome	0.0124	0.0172	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Nelfinavir—acquired immunodeficiency syndrome	0.0117	0.0163	CcSEcCtD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Ritonavir—acquired immunodeficiency syndrome	0.0112	0.0156	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.0112	0.0695	CbGpPWpGaD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.015	CcSEcCtD
Azilsartan medoxomil—Blood creatine phosphokinase increased—Lamivudine—acquired immunodeficiency syndrome	0.0103	0.0144	CcSEcCtD
Azilsartan medoxomil—AGTR1—lymphoid tissue—acquired immunodeficiency syndrome	0.0103	0.0851	CbGeAlD
Azilsartan medoxomil—AGTR1—blood—acquired immunodeficiency syndrome	0.00968	0.0801	CbGeAlD
Azilsartan medoxomil—Hyperuricaemia—Delavirdine—acquired immunodeficiency syndrome	0.00901	0.0125	CcSEcCtD
Azilsartan medoxomil—AGTR1—vagina—acquired immunodeficiency syndrome	0.00897	0.0743	CbGeAlD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00868	0.0539	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Delavirdine—acquired immunodeficiency syndrome	0.00851	0.0118	CcSEcCtD
Azilsartan medoxomil—AGTR1—lung—acquired immunodeficiency syndrome	0.00848	0.0702	CbGeAlD
Azilsartan medoxomil—AGTR1—nervous system—acquired immunodeficiency syndrome	0.00786	0.065	CbGeAlD
Azilsartan medoxomil—Blood creatinine increased—Abacavir—acquired immunodeficiency syndrome	0.00766	0.0107	CcSEcCtD
Azilsartan medoxomil—AGTR1—central nervous system—acquired immunodeficiency syndrome	0.00756	0.0626	CbGeAlD
Azilsartan medoxomil—Connective tissue disorder—Amprenavir—acquired immunodeficiency syndrome	0.00713	0.00993	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Indinavir—acquired immunodeficiency syndrome	0.00629	0.00875	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00624	0.0388	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—brain—acquired immunodeficiency syndrome	0.00601	0.0497	CbGeAlD
Azilsartan medoxomil—Blood creatinine increased—Efavirenz—acquired immunodeficiency syndrome	0.00594	0.00827	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00587	0.0365	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Nevirapine—acquired immunodeficiency syndrome	0.00585	0.00814	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00582	0.0362	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—lymph node—acquired immunodeficiency syndrome	0.0058	0.048	CbGeAlD
Azilsartan medoxomil—Angioedema—Amprenavir—acquired immunodeficiency syndrome	0.00577	0.00804	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Delavirdine—acquired immunodeficiency syndrome	0.00568	0.00791	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00566	0.00788	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Stavudine—acquired immunodeficiency syndrome	0.00564	0.00786	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.00557	0.0346	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Abacavir—acquired immunodeficiency syndrome	0.00556	0.00774	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Amprenavir—acquired immunodeficiency syndrome	0.00534	0.00744	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00526	0.0327	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Nelfinavir—acquired immunodeficiency syndrome	0.00523	0.00728	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Saquinavir—acquired immunodeficiency syndrome	0.00506	0.00704	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.00506	0.00704	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.00501	0.00697	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Zidovudine—acquired immunodeficiency syndrome	0.00491	0.00683	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Nelfinavir—acquired immunodeficiency syndrome	0.00482	0.00671	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00475	0.0296	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Nevirapine—acquired immunodeficiency syndrome	0.00473	0.00659	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Indinavir—acquired immunodeficiency syndrome	0.00456	0.00635	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.00445	0.0062	CcSEcCtD
Azilsartan medoxomil—Fatigue—Amprenavir—acquired immunodeficiency syndrome	0.00445	0.00619	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00443	0.0275	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.00438	0.0061	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Efavirenz—acquired immunodeficiency syndrome	0.00432	0.00602	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Efavirenz—acquired immunodeficiency syndrome	0.00431	0.006	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.00424	0.0059	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.00423	0.00589	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.00422	0.0263	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.00422	0.0263	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Zidovudine—acquired immunodeficiency syndrome	0.00418	0.00582	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.00417	0.0058	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00415	0.00577	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Delavirdine—acquired immunodeficiency syndrome	0.00414	0.00576	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.00411	0.0255	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.00411	0.00572	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00402	0.025	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.00402	0.025	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.004	0.00557	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Efavirenz—acquired immunodeficiency syndrome	0.00398	0.00554	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00398	0.00554	CcSEcCtD
Azilsartan medoxomil—Angioedema—Zidovudine—acquired immunodeficiency syndrome	0.00397	0.00553	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.00396	0.00552	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.00394	0.00549	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.00391	0.00544	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Indinavir—acquired immunodeficiency syndrome	0.00389	0.00541	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Ritonavir—acquired immunodeficiency syndrome	0.00382	0.00532	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Ritonavir—acquired immunodeficiency syndrome	0.00381	0.00531	CcSEcCtD
Azilsartan medoxomil—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.0037	0.00515	CcSEcCtD
Azilsartan medoxomil—Angioedema—Indinavir—acquired immunodeficiency syndrome	0.00369	0.00514	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.00367	0.00512	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Saquinavir—acquired immunodeficiency syndrome	0.00367	0.00511	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.00365	0.00508	CcSEcCtD
Azilsartan medoxomil—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00365	0.00508	CcSEcCtD
Azilsartan medoxomil—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.00364	0.00507	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00353	0.00492	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.00353	0.00491	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00353	0.0219	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.00352	0.00491	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.00352	0.0049	CcSEcCtD
Azilsartan medoxomil—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.00352	0.0049	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.00351	0.00489	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.0035	0.00488	CcSEcCtD
Azilsartan medoxomil—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.00349	0.00486	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.00348	0.00484	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.00347	0.00483	CcSEcCtD
Azilsartan medoxomil—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.00347	0.00483	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.00345	0.0048	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.00342	0.00476	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.00339	0.00472	CcSEcCtD
Azilsartan medoxomil—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00337	0.0047	CcSEcCtD
Azilsartan medoxomil—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.00334	0.00465	CcSEcCtD
Azilsartan medoxomil—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00333	0.00463	CcSEcCtD
Azilsartan medoxomil—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00325	0.00453	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.00325	0.00452	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00325	0.00452	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00325	0.0202	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00324	0.0045	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.00323	0.0045	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00322	0.00448	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.0032	0.00446	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00319	0.0198	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.00313	0.00435	CcSEcCtD
Azilsartan medoxomil—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00306	0.00426	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00306	0.00426	CcSEcCtD
Azilsartan medoxomil—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00306	0.00426	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00306	0.00426	CcSEcCtD
Azilsartan medoxomil—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00303	0.00422	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00303	0.00421	CcSEcCtD
Azilsartan medoxomil—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00299	0.00416	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.00298	0.00415	CcSEcCtD
Azilsartan medoxomil—Rash—Didanosine—acquired immunodeficiency syndrome	0.00296	0.00413	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00296	0.00412	CcSEcCtD
Azilsartan medoxomil—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00294	0.00409	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00294	0.0183	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00293	0.00408	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.0029	0.00403	CcSEcCtD
Azilsartan medoxomil—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.0029	0.00403	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00289	0.00403	CcSEcCtD
Azilsartan medoxomil—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00289	0.00402	CcSEcCtD
Azilsartan medoxomil—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00288	0.00402	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00286	0.00398	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.00285	0.00396	CcSEcCtD
Azilsartan medoxomil—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00284	0.00396	CcSEcCtD
Azilsartan medoxomil—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.00284	0.00396	CcSEcCtD
Azilsartan medoxomil—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.00284	0.00395	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.0028	0.0039	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00279	0.00389	CcSEcCtD
Azilsartan medoxomil—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00279	0.00389	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00276	0.0172	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00276	0.0172	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00275	0.00383	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00275	0.00383	CcSEcCtD
Azilsartan medoxomil—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00271	0.00377	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.0027	0.00377	CcSEcCtD
Azilsartan medoxomil—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.0027	0.00376	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.00269	0.00375	CcSEcCtD
Azilsartan medoxomil—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.00269	0.00374	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00269	0.0167	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.00268	0.00373	CcSEcCtD
Azilsartan medoxomil—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00267	0.00371	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00266	0.00371	CcSEcCtD
Azilsartan medoxomil—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00266	0.0037	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00262	0.00365	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.0026	0.00362	CcSEcCtD
Azilsartan medoxomil—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00258	0.00359	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00258	0.00359	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00258	0.00359	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00257	0.00358	CcSEcCtD
Azilsartan medoxomil—Rash—Stavudine—acquired immunodeficiency syndrome	0.00257	0.00358	CcSEcCtD
Azilsartan medoxomil—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.00257	0.00358	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00257	0.00358	CcSEcCtD
Azilsartan medoxomil—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00255	0.00354	CcSEcCtD
Azilsartan medoxomil—Rash—Abacavir—acquired immunodeficiency syndrome	0.00253	0.00353	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00253	0.00353	CcSEcCtD
Azilsartan medoxomil—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00251	0.0035	CcSEcCtD
Azilsartan medoxomil—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00251	0.00349	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00248	0.00346	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	0.00248	0.0154	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.00246	0.00342	CcSEcCtD
Azilsartan medoxomil—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00243	0.00339	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00243	0.0151	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.00243	0.00338	CcSEcCtD
Azilsartan medoxomil—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00242	0.00337	CcSEcCtD
Azilsartan medoxomil—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00239	0.00332	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00238	0.00331	CcSEcCtD
Azilsartan medoxomil—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.00238	0.00331	CcSEcCtD
Azilsartan medoxomil—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00237	0.0033	CcSEcCtD
Azilsartan medoxomil—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00235	0.00327	CcSEcCtD
Azilsartan medoxomil—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00233	0.00325	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	0.00232	0.0144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.0023	0.0143	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.00229	0.00319	CcSEcCtD
Azilsartan medoxomil—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.00229	0.00319	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00227	0.0141	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00226	0.00314	CcSEcCtD
Azilsartan medoxomil—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00224	0.00311	CcSEcCtD
Azilsartan medoxomil—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00224	0.00311	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00223	0.00311	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	0.00221	0.0137	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00221	0.00307	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00219	0.00304	CcSEcCtD
Azilsartan medoxomil—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.00218	0.00304	CcSEcCtD
Azilsartan medoxomil—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00218	0.00304	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00218	0.0135	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00216	0.0134	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00214	0.00298	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00213	0.00297	CcSEcCtD
Azilsartan medoxomil—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00211	0.00294	CcSEcCtD
Azilsartan medoxomil—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00211	0.00293	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.0021	0.0131	CbGpPWpGaD
Azilsartan medoxomil—Rash—Indinavir—acquired immunodeficiency syndrome	0.00208	0.0029	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00208	0.00289	CcSEcCtD
Azilsartan medoxomil—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00206	0.00287	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00204	0.00284	CcSEcCtD
Azilsartan medoxomil—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.00198	0.00275	CcSEcCtD
Azilsartan medoxomil—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00197	0.00275	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00197	0.0122	CbGpPWpGaD
Azilsartan medoxomil—Rash—Efavirenz—acquired immunodeficiency syndrome	0.00197	0.00274	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.00196	0.00273	CcSEcCtD
Azilsartan medoxomil—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00196	0.00273	CcSEcCtD
Azilsartan medoxomil—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00195	0.00272	CcSEcCtD
Azilsartan medoxomil—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.0019	0.00265	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00189	0.0118	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00189	0.00263	CcSEcCtD
Azilsartan medoxomil—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00188	0.00262	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00188	0.00262	CcSEcCtD
Azilsartan medoxomil—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00188	0.00261	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00185	0.0115	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00185	0.0115	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00185	0.00258	CcSEcCtD
Azilsartan medoxomil—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00182	0.00254	CcSEcCtD
Azilsartan medoxomil—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00182	0.00253	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00182	0.00253	CcSEcCtD
Azilsartan medoxomil—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00179	0.00249	CcSEcCtD
Azilsartan medoxomil—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00177	0.00247	CcSEcCtD
Azilsartan medoxomil—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00176	0.00244	CcSEcCtD
Azilsartan medoxomil—Rash—Ritonavir—acquired immunodeficiency syndrome	0.00174	0.00242	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.00174	0.00242	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.00173	0.00241	CcSEcCtD
Azilsartan medoxomil—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00167	0.00233	CcSEcCtD
Azilsartan medoxomil—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00167	0.00233	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00167	0.00233	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00166	0.0103	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00164	0.00228	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	0.00161	0.00999	CbGpPWpGaD
Azilsartan medoxomil—Rash—Lamivudine—acquired immunodeficiency syndrome	0.0016	0.00222	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.0016	0.00222	CcSEcCtD
Azilsartan medoxomil—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00158	0.00219	CcSEcCtD
Azilsartan medoxomil—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.0015	0.00209	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.0015	0.00933	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00148	0.00921	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00141	0.00877	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00141	0.00877	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00141	0.00876	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00138	0.00857	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00134	0.00835	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00127	0.00789	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00125	0.00775	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00107	0.00667	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000967	0.00601	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000851	0.00529	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000848	0.00527	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000814	0.00506	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000814	0.00506	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000797	0.00495	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000797	0.00495	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00077	0.00479	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000736	0.00458	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000724	0.0045	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000724	0.0045	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000606	0.00377	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000597	0.00371	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000582	0.00362	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000551	0.00342	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000546	0.0034	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000542	0.00337	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000503	0.00313	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000496	0.00308	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000455	0.00283	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000428	0.00266	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000428	0.00266	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000325	0.00202	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.00032	0.00199	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000316	0.00196	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000293	0.00182	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000287	0.00178	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000169	0.00105	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000168	0.00105	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.95e-05	0.000619	CbGpPWpGaD
